Further, the European Leukaemia Net 2017 risk stratification of AML includes recurring mutations in six genes (FLT3, CEBPA, NPM1, RUNX1, ASXL1 and TP53), and the well-characterized cytogenetic changes [6]. Here, RUNX1 is linked to acute myeloid leukemia.